A downgrade from Leerink Swann to Market Perform from Outperform adds to Sarepta Therapeutics'...

|About: Sarepta Therapeutics, Inc. (SRPT)|By:, SA News Editor

A downgrade from Leerink Swann to Market Perform from Outperform adds to Sarepta Therapeutics' (SRPT) problems. The FDA's request has "prolonged uncertainty" and the need to run a Phase III trial preapproval could give GlaxoSmithKline (GSK) and Prosensa's drisapersen treatment a first-to-market advantage. SRPT shares now -10.17% premarket.